Investor Information
DiagnoCure Oncology Laboratories is a wholly-owned subsidiary of DiagnoCure Inc., a company listed on the Toronto Stock Exchange under the ticker CUR.
DiagnoCure Inc. is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. In addition to the Previstage™ GCC Colorectal Cancer Staging Test, recently launched by DiagnoCure Oncology Laboratories, the Company also has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure’s proprietary molecular marker. This test is also available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA™ PCA3 in vitro assay, and in Canada. For more information, visit www.diagnocure.com.
Investors Contact
General shareholder information
DiagnoCure Inc.
2050 René-Lévesque Blvd W., 6th floor
Québec (Québec) G1V 2K8 Canada
Phone: (418) 527-6100
Toll-free: 1-888-900-6626 (Canada and United States)
Fax: (418) 527-0240
E-mail: communications@diagnocure.com
Web site: www.diagnocure.com
Investor relations
JF Bureau
Senior Vice President and Chief Financial Officer
(418) 527-6100
Registrar and transfer agent
Computershare Trust Company of Canada
1500 University Street, 7th floor
Montréal (Québec) H3A 3S8
Phone: (514) 982-7888